Roumeliotou-Karayannis A, Dandolos E, Richardson S C, Papaevangelou G
Vaccine. 1986 Jun;4(2):93-4. doi: 10.1016/0264-410x(86)90044-7.
We report a trial of a reduced dose (2.5 micrograms) of recombinant hepatitis B vaccine, carried out over seven months in 54 males aged 17 to 19 years. Response to the reduced dose was significantly inferior to that found in equivalent trials of 5 and 10 micrograms doses. Although all seroconverted, three participants (6%) remained below the protective level of 10 IU l-1 of antibody to hepatitis B surface antigen (anti-HBs) and a further eight (15%) below 100 IU l-1, possibly requiring early revaccination. The final geometric mean titre of anti-HBs was 810 IU l-1 (95% confidence interval, 433 to 1520). It appears that 2.5 micrograms may be too low a dosage for general use in adults.
我们报告了一项针对17至19岁男性的重组乙型肝炎疫苗低剂量（2.5微克）试验，该试验历时七个月，涉及54名男性。低剂量疫苗的反应明显低于5微克和10微克剂量的等效试验结果。虽然所有人都发生了血清转化，但有三名参与者（6%）的乙型肝炎表面抗原抗体（抗-HBs）水平仍低于10 IU l-1的保护水平，另有八名参与者（15%）低于100 IU l-1，可能需要尽早重新接种疫苗。抗-HBs的最终几何平均滴度为810 IU l-1（95%置信区间，433至1520）。看来2.5微克的剂量对成年人普遍使用来说可能过低。
